A Post-Market Study of Transcatheter Perivascular Renal Denervation for the Treatment of Hypertension Using the Ablative Solutions Inc. Peregrine System™ Infusion Catheter
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 45
- 试验地点
- 20
- 主要终点
- Number of Subjects With the Absence of Particular Events as Adjudicated by the CEC Through 1-month Post Procedure:
研究概览
简要总结
The Ablative Solutions, Inc. Peregrine System Infusion Catheter is a catheter-based device which is intended to be used to ablate the afferent and efferent sympathetic nerves serving the kidneys. The catheter is inserted via the femoral artery, steered into the renal artery, and then delivers, by infusion from its distal end, a neurolytic agent. This targets the nerve bundles, which are in the adventitia - a sheath surrounding the artery. The aim is to reduce blood pressure in cases of hypertension, including seriously elevated blood pressure which does not respond to drug treatment. This study will evaluate the safety and performance of the device.
详细描述
There is strong evidence in the published literature that the renal nerves are important contributors to hypertension, and that their ablation does not have adverse side-effects.
The literature provides technical, clinical and scientific evidence supporting the use of perivascular renal denervation for a carefully defined patient group.
An existing device (the Medtronic Symplicity catheter) was initially shown to be safe and effective for achieving perivascular renal denervation by delivery of radio-frequency energy. The results of early nonrandomized clinical studies (HTN-1, HTN-2) found that perivascular renal denervation by radio-frequency energy delivery was an effective therapy, associated with very low risks. In other contexts, denervation can also be safely and effectively achieved by neurolytic agents.
The ASI Peregrine System™ Infusion Catheter and the denervation procedure in general is similar enough to the Medtronic Symplicity catheter to enable the use of published data to establish the validity of the design concept of the Peregrine System and estimate the likely levels of risk of side effects. It can be concluded from the literature that the ASI Peregrine System™ will achieve percutaneous renal denervation with a low risk of procedural complications (comparable to accepted percutaneous interventional therapies) and without long-term impairment of renal artery or kidney function or other serious adverse events.
Previous premarket clinical trials have provided support for the safe and effective use of the Peregrine Catheter for the treatment of patients with hypertension. The Peregrine System Infusion Catheter is currently CE marked and the indication for use is "The Peregrine System™ Infusion Catheter is intended for the infusion of a neurolytic agent to achieve a reduction in systemic blood pressure in hypertensive patients." Based upon the literature and previous clinical data, chemical denervation is an appropriate treatment for the specified study population of adults who have hypertension despite taking at least 3 anti-hypertensive drugs of different classes including at least one diuretic.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 80 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Adult subject, age 18-80, male or female;
- •Subject has a target treatment vasculature diameter of ≥4 mm and ≤ 7 mm and length of ≥5 mm;
- •Subject has 3 measurements with a mean of office Systolic Blood Pressure of
- •≥150 mmHg AND office Diastolic Blood Pressure of ≥85 mmHg;
- •Subject has a 24-hour mean systolic Ambulatory Blood Pressure Measurement (ABPM) ≥135 mm Hg with ≥70% valid readings (as determined by measurement device);
- •Subject with hypertension is receiving and adhering to a stable medication regimen of at least 3 anti-hypertensive medications of different classes (for at least 4 consecutive weeks), one of which must be a diuretic;
- •Subject agrees to have all study procedures performed, to comply with medication regimen and is able and willing to comply with all study follow-up visits;
- •Subject has provided written informed consent.
排除标准
- •Subject has a contraindication known for conventional percutaneous interventional procedures such as:
- •intolerance for antiplatelet/anticoagulant therapy
- •known allergy to contrast media
- •bleeding disorders (such as bleeding diathesis, thrombocytopenia and severe anemia)
- •Subject has documented severe untreated obstructive sleep apnea (Apnea Hypopnea Index [AHI] ≥30 per hour);
- •Subjects with nephrotic syndrome;
- •Subjects on immunosuppressive medications or immunosuppressive doses of steroids;
- •Subject has type 1 diabetes mellitus;
- •Subject is pregnant or nursing or planning to become pregnant;
- •Subject has an eGFR ≤20 mL/min/1.73m2
- •, based on the CKD-EPI equation;
- •Subject has imaging-assessed renal artery anatomy abnormalities or variations based on Investigator's evaluation of the screening images [i.e. MRA/CTA examination and/or renal angiography]) meeting one of the following criteria:
- •Renal artery stenosis >60% of the normal diameter segment (diameter stenosis, compared to the angiographically normal proximal or distal segment);
- •Any renal artery abnormality or disease that, per the physician assessment, precludes the safe insertion of the guiding catheter (such as but not limited to severe renal artery aneurysm, excessive tortuosity, severe renal artery calcification);
- •Previous renal angioplasty associated with stenting or other implants, that, per the physician's assessment, precludes the safe deployment of the Peregrine catheter components in the target treatment segment of the renal artery;
- •Subject has a history of nephrectomy, a single kidney or kidney tumor, or urinary tract obstruction (with potential for hydronephrosis);
- •Subject is known to have a non-functioning kidney or unequal renal size (>2 cm difference in renal length between kidneys associated with a chronic kidney disease or a deterioration of the kidney function);
- •Subject has a renal transplant;
- •Subject has a history of myocardial infarction, unstable angina pectoris, or stroke/TIA within the last six months from planned procedure;
- •Subject has hemodynamically significant valvular heart disease;
- •Subject has heart failure (NYHA III or IV) or has an ejection fraction ≤30%;
- •Subject with chronic atrial fibrillation;
- •Subjects who are allergic or intolerant of the neurolytic agent (such as dehydrated alcohol);
- •Any contraindication to the imaging as required per the protocol;
- •Subject has a life expectancy of <12 months;
- •Subject is currently enrolled in other potentially confounding research, i.e., another therapeutic or interventional research trial. Subjects enrolled in observational registries may still be eligible.
结局指标
主要结局
Number of Subjects With the Absence of Particular Events as Adjudicated by the CEC Through 1-month Post Procedure:
时间窗: 1-month
The primary safety endpoint is defined by the absence of any of the following events as adjudicated by the CEC through 1-month post procedure: 1. Peri-procedural major vascular complications; 2. Major Bleeding as defined by the TIMI Bleeding Classification; 3. Acute Kidney Injury (AKI) within 1 month of the procedure 4. Peri-procedural death (within 1 month of the procedure)
Change in 24-hour Mean Ambulatory Systolic Blood Pressure From Baseline to 6 Months
时间窗: 6 months
The primary performance endpoint is defined as a reduction of 24-hour mean ambulatory systolic blood pressure following treatment at 6 months, as compared to baseline.
次要结局
- Change in Serum Creatinine From Baseline to 6 Months(6 months)
- Change in Albuminuria Categorization(3, 6, and 12 months)
- Change in eGFR(1, 3, 6 and 12 months)
- Numbr of Subjects With a Decline in eGFR by >25% From Baseline to 6 Months(6 months)
- Number of Participants With New Renal Arterial Stenosis > 60%(6 months)
- Number of Subjects With Stroke or Transient Ischemic Attack (TIA) With 1 Month of the Procedure(1 month)
- Number of Subjects With Myocardial Infarction (MI) Within 1 Month of the Procedure(1 month)
- Changes in Systolic and Diastolic Clinic/Office Blood Pressure(7-day, 1, 3, 6 and 12 months)
- Changes in Systolic and Diastolic 24-hour Mean Daytime and Nighttime Ambulatory Blood Pressure(1, 3, 6 and 12-months)
- Changes in Diastolic 24-hour Mean Ambulatory Blood Pressure(1, 3, 6 and 12-months)
- Number of Participants With Major Adverse Events (MAE) Through 6 Months Post-Procedure(6 months)
- Changes in Antihypertensive Medications at 7 Days, and 1, 3, 6 and 12 Months Post-Procedure(7-day, 1, 3, 6 and 12 months)
- Changes in Systolic 24-hour Mean Ambulatory Blood Pressure(1, 3 and 12 months)
- The Progression of Kidney Disease(1, 3, 6, and 12 months)
- Change in Albuminuria(3, 6, and 12 months)
- Change in Serum Creatinine and Cystatin-C(3, 6, and 12 months)